---
title: 'Nanoliposomal irinotecan and fluorouracil plus leucovorin versus fluorouracil
  plus leucovorin in patients with cholangiocarcinoma and gallbladder carcinoma previously
  treated with gemcitabine-based therapies (AIO NALIRICC): a multicentre, open-label,
  randomised, phase 2 trial'
date: '2024-06-13'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38870977/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240614182310&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: 'BACKGROUND: There is an unmet need for effective therapies in pretreated
  advanced biliary tract cancer. We aimed to evaluate the efficacy of nanoliposomal
  irinotecan and fluorouracil plus leucovorin compared with fluorouracil plus leucovorin
  as second-line treatment for biliary tract ...'
disable_comments: true
---
BACKGROUND: There is an unmet need for effective therapies in pretreated advanced biliary tract cancer. We aimed to evaluate the efficacy of nanoliposomal irinotecan and fluorouracil plus leucovorin compared with fluorouracil plus leucovorin as second-line treatment for biliary tract ...